Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Atypical Hemolytic Uremic Syndrome Clinical Trial

— aHUS-iPSC-EC  

Official title:

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05805202
• Other study ID #: aHUS-iPSC-EC
• Status: Recruiting
• Phase: N/A
• Start date: April 6, 2023
• Est. completion date: March 2025

Study information

• Verified date: April 2023
• Source: Mario Negri Institute for Pharmacological Research
• Contact: Marina Noris, Dr.
• Phone: +3903545351
• Email: marina.noris[@]marionegri.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hemolytic Uremic Syndrome (HUS) is a rare disease characterized by rupture of red blood cells (hemolytic anemia), low platelet count (thrombocytopenia), and thrombotic occlusion of small vessels (thrombotic microangiopathy), with prevalent involvement of the kidneys.

SEU, in its typical form is caused by gastrointestinal infection with Escherichia coli.

The atypical form of SEU (aSEU), which is not caused by an Escherichia coli infection, is a very rare disease that may have a genetic origin; it affects both children and adults and may occur in a sporadic or familial form. Many studies have shown that about 60% of cases of atypical HUS are associated with genetic abnormalities of the complement system (particularly the so-called "alternative pathway"), which is a key part of the immune system for responding to infection. Complement consists of a series of proteins that, when activated, create a so-called "cascade," which leads to the elimination of the infectious agent, either directly or through other cells. Complement is finely regulated in such a way as to prevent damage to healthy cells in one's own body. Genetic defects in some of these complement regulatory proteins cause reduced protection of the endothelial surface (thus the vessel wall) against complement activation.

Recently, new mutations have been described in a gene unrelated to the complement pathway, the DKGE gene, which codes for the intracellular isoform of diacylglycerol kinase . In these patients, small renal vessel occlusion appears to occur as a result of altered endothelial cell proliferation and angiogenesis through mechanisms apparently unrelated to complement activation. However, to date these mechanisms are poorly studied. Throughout the entire project statistical methods will be applied to optimize the characterization of the abnormalities in phenotype and function of iPSC-EC derived from aHUS patients with either DGKE or MCP genetic abnormalities as compared with control iPSC-EC, including identifying potential drugs that could correct the abnormalities

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Adults and children with aHUS defined by history of microangiopathic hemolytic anemia and thrombocytopenia (hematocrit (Ht) <30%, hemoglobin (Hb) <10 g/dL, LDH >500 IU/L, undetectable haptoglobin, fragmented erythrocytes in the peripheral blood smear with negative Coomb's test, and platelet count <150,000/microL), associated with acute renal failure.

• Written informed consent

Exclusion Criteria:

• TTP (ADAMTS13 activity <10%)

• STEC-HUS (presence of stx and eae genes or Shiga-toxin in the stools and/or serum antibodies against Shiga-toxin and/or STEC LPS).

• Disseminated intravascular coagulation (prolonged thromboplastin time and lower than normal fibrinogen levels).

Related Conditions & MeSH terms

• Atypical Hemolytic Uremic Syndrome
• Hemolysis
• Hemolytic-Uremic Syndrome

Intervention

Other:
• Blood sampling and urine analysis
A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees

Locations

Country	Name	City	State
Italy	Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"	Ranica	BG

Sponsors (1)

Lead Sponsor	Collaborator
Mario Negri Institute for Pharmacological Research

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Generation and characterization of patient-specific and healthy donor iPSC		once during the study
Primary	Differentiation of iPSC into endothelial cells		once during the study
Primary	Characterizationof iPSC into endothelial cells		once during the study
Primary	Cell culture viability		once during the study